Skip to main content
. 2022 Apr 14;14(8):1647. doi: 10.3390/nu14081647

Table 2.

Findings of fecal microbiota transplant (FMT) in relation to myasthenia gravis (MG) using mice.

Findings
Animal study on a FMT Using an open field test, 4 weeks after a FMT [97]
  • -

    Colonization of b GF mice with c MMb resulted in an impaired locomotion ability.

  • -

    The effect may be reversed by colonizing b GF mice with both c MMb and d HMb.

  • -

    Levels of e TNF-α, f IFN-γ, and g IL-10 in both serum and intestinal tissue were much greater in the c MMb group than the d HMb group. The co-administration of d HMb could reverse the effects of increased cytokines in c MMb mice.

16S rRNA gene sequencing, 4 weeks after a FMT [97]
  • -

    Distinct microbial communities of MG patients were reproducible in a FMT, c MMb, and d HMb mice.

  • -

    A total of 98 h OTUs belonging to Firmicutes (49/98), Bacteroides (34/98), and Actinobacteria (3/98) were identified.

  • -

    A total of 54 of the 98 differential h OTUs between c MMb and d HMb were reversed in the i CMb group

  • -

    A total opf 16 of the 54 reversed h OTUs belonging to Lachnospiraceae (7 h OTU), Bacteroidaceae (4 h OTU), and Ruminococcaceae (2 h OTU) were associated with impaired locomotion ability and the interference of fecal metabolomics.

a FMT: fecal microbiota transplant; b GF: germ-free; c MMb: myasthenia gravis microbiome; d HMb: healthy microbiota; e TNF-α: tumor necrosis factor alpha; f IFN-γ: interferon gamma; g IL-10: interleukin 10; h OTU: Operational Taxonomic Unit; i CMb: both healthy microbiota and myasthenia gravis microbiome.